Deals, Partnering

Development and manufacturing agreement for mAb TMB-360

Posted on 07 August 2014


EirGenix has signed the agreement with TaiMed Biologics to provide development and manufacturing services for TaiMed’s second generation anti-HIV monoclonal antibody, TMB-360.

The scope of this collaboration project includes cell line development, process development and scale-up for manufacturing to provide materials for pre-clinical and clinical studies.

Compared to the first generation anti-HIV mAb, TMB-355, the new generation drug possesses significant improvements in terms of overcoming anti-drug resistance, efficiency and pharmacokinetics;

with these advantages, TMB-360 will become a stronger successor to TMB-355 to benefit patients diagnosed with AIDS.

By utilizing EirGenix’s development platforms and manufacturing services, it is anticipated TMB-360 will reach the market well within the expected schedule.

Report Monoclonal Antibodies Partnering Terms and Agreements

Report: Cancer Monoclonal Antibody Partnering Terms and Agreements

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply